Cll ipi Calculator: Free oncology Risk Score & Interpretation

CLL-IPIInternational Prognostic Index for CLL

Demographics & Serology

Ageyears

Beta-2 Microglobulinmg/L

Cutoff: 3.5 mg/L

Genetics & Staging

Awaiting Data

The CLL-IPI integrates genetic, biochemical, and clinical markers to stratify newly diagnosed CLL.

Scoring Highlights

TP53 aberration: 4 points
IGHV unmutated: 2 points
Beta-2M > 3.5 mg/L: 2 points

Guidelines & Evidence

Verified

Last Review: 2026

When to Use

Clinical Use

Baseline risk stratification for all patients with newly diagnosed CLL.

Aiding the decision of when to initiate treatment (though not a substitute for iwCLL treatment indications).

Selecting between chemo-immunotherapy (FCR/BR) and novel agents (BTK inhibitors or Venetoclax).

How it Works

Weighted Scoring Variables

Variable	Points Assigned
TP53 Status (Deletion or Mutation)	4
IGHV Mutational Status (Unmutated)	2
Serum Beta-2 Microglobulin (> 3.5 mg/L)	2
Clinical Stage (Binet B/C or Rai I-IV)	1
Age (> 65 years)	1

Clinical Pearls

Therapeutic Implications

Risk Group	Score	Typical Strategy
Low	0 - 1	Watch and Wait.
Intermediate	2 - 3	Watch and Wait (unless symptomatic).
High	4 - 6	Treat with targeted agents (if symptomatic).
Very High	7 - 10	Prioritize clinical trials or BTK/BCL-2 inhibitors; Avoid chemo.

TP53 vs. The Rest

The 4-point weighting for TP53 is the most critical feature. Patients with TP53 disruption have notoriously poor responses to chemotherapy (FCR/BR). Even a young, fit patient with TP53 disruption is "Very High Risk" and should be managed with targeted therapy from the start.

Last Comprehensive Review: 2026

CLL-IPIInternational Prognostic Index for CLL

Demographics & Serology

Ageyears

Beta-2 Microglobulinmg/L

Cutoff: 3.5 mg/L

Genetics & Staging

Awaiting Data

The CLL-IPI integrates genetic, biochemical, and clinical markers to stratify newly diagnosed CLL.

Scoring Highlights

TP53 aberration: 4 points
IGHV unmutated: 2 points
Beta-2M > 3.5 mg/L: 2 points

Guidelines & Evidence

Verified

Last Review: 2026

When to Use

Clinical Use

Baseline risk stratification for all patients with newly diagnosed CLL.

Aiding the decision of when to initiate treatment (though not a substitute for iwCLL treatment indications).

Selecting between chemo-immunotherapy (FCR/BR) and novel agents (BTK inhibitors or Venetoclax).

How it Works

Weighted Scoring Variables

Variable	Points Assigned
TP53 Status (Deletion or Mutation)	4
IGHV Mutational Status (Unmutated)	2
Serum Beta-2 Microglobulin (> 3.5 mg/L)	2
Clinical Stage (Binet B/C or Rai I-IV)	1
Age (> 65 years)	1

Clinical Pearls

Therapeutic Implications

Risk Group	Score	Typical Strategy
Low	0 - 1	Watch and Wait.
Intermediate	2 - 3	Watch and Wait (unless symptomatic).
High	4 - 6	Treat with targeted agents (if symptomatic).
Very High	7 - 10	Prioritize clinical trials or BTK/BCL-2 inhibitors; Avoid chemo.

TP53 vs. The Rest

Last Comprehensive Review: 2026

CLL-IPI

Demographics & Serology

Genetics & Staging

When to Use

Clinical Use

How it Works

Weighted Scoring Variables

Clinical Pearls

Therapeutic Implications

TP53 vs. The Rest

The Evidence

Key Reference

An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data

Related Tools

Recent Journal Updates

CLL-IPI

Demographics & Serology

Genetics & Staging

When to Use

Clinical Use

How it Works

Weighted Scoring Variables

Clinical Pearls

Therapeutic Implications

TP53 vs. The Rest

The Evidence

Key Reference

An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data

Related Tools

Recent Journal Updates